EUVIMEDEUVIMED entdecken
Kohortenstudie

Relapse risk after glucocorticoid withdrawal in stable Sjögren’s disease-associated interstitial lung disease: a retrospective cohort study in China

Ningxin Li, Hui Huang, Yimeng Jia, Lidan Zhao, Huaxia Yang, Wen Zhang, Yunyun Fei

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-025-07916-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Ningxin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical …. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Glucocorticoids, Sjogren's Syndrome. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To explore the risk of relapse after glucocorticoids (GCs) withdrawal in patients with stable Sjögren's disease-associated interstitial lung disease (SjD-ILD). METHODS: This was a single-center, retrospective cohort study conducted at Peking Union Medical College Hospital between February 2016 and January 2024. The study compared two treatment strategies for patients with stable SjD-ILD: GC withdrawal versus GC maintenance. The primary endpoint was to compare the relapse rates between the two groups over a 3-year follow-up period. The secondary endpoints included changes in pulmonary function, serological markers, and adverse events. RESULTS: A total of 134 patients were included in this study, with 61 in the GC withdrawal group and 73 in the GC maintenance group. Over the 3-year follow-up, 16 patients (27.93%) in the withdrawal group and 19 patients (28.77%) in the maintenance group experienced a relapse. No significant difference was found in relapse rates between the two groups (HR = 1.011, 95% CI 0.517-1.977, p = 0.974). Changes in pulmonary function, ESR, hs-CRP, C3, and C4 levels showed no significant differences, while IgG changes differed at the 2- and 3-year follow-up (p < 0.05). Adverse event rates were similar between groups. CONCLUSIONS: GCs' withdrawal in patients with stable SjD-ILD did not increase the relapse risk compared to continuing low-dose GCs' therapy. These findings suggest that cautious GCs' withdrawal might be a viable option for patients with stable, clinically inactive SjD-ILD. Key Points • Glucocorticoid withdrawal in stable pSS-ILD did not increase relapse risk compared to continuing low-dose GC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialGlucocorticoidsSjogren's SyndromeHumansRetrospective StudiesFemaleMaleMiddle AgedRecurrenceChinaAgedAdult

Stichwörter der Autor:innen

Glucocorticoids withdrawalRelapse riskRetrospective cohort studySjögren’s disease-associated interstitial lung disease

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. feiyunyun@pumch.cn.
  • The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China. feiyunyun@pumch.cn.
  • Department of Heath Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. feiyunyun@pumch.cn.

Zitieren

APA

Li, N., Huang, H., Jia, Y., Zhao, L., Yang, H., Zhang, W., & Fei, Y. (2026). Relapse risk after glucocorticoid withdrawal in stable Sjögren’s disease-associated interstitial lung disease: a retrospective cohort study in China. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07916-9

Vancouver

Li N, Huang H, Jia Y, Zhao L, Yang H, Zhang W, et al. Relapse risk after glucocorticoid withdrawal in stable Sjögren’s disease-associated interstitial lung disease: a retrospective cohort study in China. Clinical Rheumatology. 2026. doi:10.1007/s10067-025-07916-9

BibTeX
@article{Li2026,
  author = {Li, Ningxin and Huang, Hui and Jia, Yimeng and Zhao, Lidan and Yang, Huaxia and Zhang, Wen and Fei, Yunyun},
  title = {Relapse risk after glucocorticoid withdrawal in stable Sjögren’s disease-associated interstitial lung disease: a retrospective cohort study in China},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-025-07916-9}
}
Kostenlos starten →